Health Condition 1: C92- Myeloid leukemia
Conditions
Interventions
Intervention1: CPI-613® (Devimistat): Induction and Consolidation: CPI-613® (devimistat): 2,000 mg/m2 over 2 hours as a central line IV infusion): 5 doses, once a day (QD) Days 1 to 5
High Dose Cyta
Sponsors
Rafael Pharmaceuticals Inc
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient has provided an informed consent prior to initiation of any study specific activities/procedures. 2. Males and females age >= 50 years must have histologically documented AML that is relapsed from, or refractory to, prior standard therapies. 3. Refractory is defined as failure to achieve CR or CRi following a. Two standard dose Cytarabine based induction cycles or one HiDAC based cycle or, b. Persistent disease after one cycle of standard dose cytarabine (defined as no decrease in marrow blast percentage from diagnosis on Day 14 marrow) or, c. Persistent disease after at least 2 cycles of a hypomethylating agent (azacytidine or decitabine) with or without venetoclax. 4. Relapse is defined as development of recurrent AML (as described by Döhner et al, 2017) after CR or CRi has been achieved with a prior chemotherapy or after disease progression on a hypomethylating agent with or without venetoclax. 5. ECOG PS 0-2 6. Expected survival greater than 3 months. 7. Women of child-bearing potential (i.e. women who are pre-menopausal or Examples are use of oral, injected or implanted hormonal methods of contraception, placement of an intra uterine device or intra uterine system, male partner sterilization, true abstinence during and for 6 months after the last administered dose of CHAM or HAM therapy and must have a negative serum pregnancy test within 1 week prior to treartment initiation and at first day of each cycle and at the end of systemic exposure. (Note: Pregnant patients are excluded because the effects of CPI-613® (devimistat) on a fetus are unknown. 8. Fertile men who are sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository during the study period and up to 6 months after completion of the study screening, unless documentation of infertility exists 9. Good state of mental health, ability to understand and willingness to sign the informed consent form (ICF). 10. No radiotherapy, treatment with cytotoxic chemotherapy, treatment with biologic agents or any anti-cancer therapy within the 1 week prior to treatment with CPI-613® (devimistat). Hydroxyurea and oral tyrosine kinase (FLT3) or Isocitrate Dehydrogenase 1 and 2 (IDH1/2) inhibitors being used with Grade 11. Laboratory values a. Adequate hepatic function (aspartate aminotrans
Exclusion criteria
Exclusion criteria: 1. Patients who have received cytotoxic chemotherapy treatment for their current relapsed or refractory AML. (Treatment with hypomethylating agents (decitabine or azacytidine) either alone or in combination with venetoclax is allowed. Targeted therapies including FLT3 or IDH1/2 inhibitors or Hydrea or venetoclax are allowed. Targeted therapies and Hydrea may be taken until the day prior to starting CHAM or HAM therapy) . 2. Vulnerable adult and patient whose health conditions does not allow them to give their consent. 3. History or evidence of any other clinically significant disorder, condition or disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patientsâ?? risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion. 4. Patients with active Central Nervous System (CNS) involvement (leukemic infiltration, blast in the spinal fluid). 5. Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g active peptic ulcer disease) bleeding diathesis (e.g. active peptic ulcer disease). 6. Female patients who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 months after the last dose of CHAM or HAM therapy (the teratogenic potential of CPI-613® (devimistat) is unknown). Female patients of childbearing potential with a positive pregnancy test assessed by a serum pregnancy test at Screening. 7. Women of childbearing potential (i.e. women who are pre-menopausal or 8. Male patients with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for 6 months after completion of CHAM or HAM therapy. 9. Male patients unwilling to abstain from donating sperm during treatment and for 6 months after completion of CHAM or HAM therapy with potential highest teratogenic risk. 10. Known hypersensitivity to study treatment drugs or any of the excipient(s) contained in the drug formulation. 11. Life expectancy less than 3 months. 12. Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients. 13. Unwilling or unable to follow protocol requirements. 14. Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly). 15. Patients with any amount of clinically significant pericardial effusion that requires drainage. 16. Evidence of ongoing, uncontrolled bacterial, viral or fungal infection. 17. Patients with known human immunodeficiency virus infection. 18. History of other malignancy within the past 5 years, with the following exception(s): a. Malignancy treated with curative intent and with no known active disease present for >= 5 years before enrolment and felt to be at low risk for recurrence
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| OS (Overall survival) CR and CRh (Complete remission and Complete remission with partial hematologic recovery) SafetyTimepoint: From date of randomization to date of death 36 months after first randomization | — |
Primary
| Measure | Time frame |
|---|---|
| CRTimepoint: a. 1st Interim Analysis: 14 months after first randomization b. 2nd Interim Analysis: 25 months after first randomization c. 3rd Interim Analysis: 36 Months after first randomization | — |
Countries
Australia, Austria, Belgium, Canada, France, Germany, India, Italy, Poland, Republic of Korea, Spain, United States of America
Contacts
Public ContactDr Shariq Anwar
JSS Medical Research India Private Limited
Outcome results
None listed